Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis
暂无分享,去创建一个
Lucas M Bachmann | Gerben ter Riet | Jos Kleijnen | Milo A Puhan | J. Kleijnen | M. Puhan | G. ter Riet | L. Bachmann | A. Kessels | Alphons G Kessels
[1] J. van der Palen,et al. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. , 2002, American journal of respiratory and critical care medicine.
[2] T. Lasserson,et al. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. , 2007, The Cochrane database of systematic reviews.
[3] L. Stewart,et al. To IPD or not to IPD? , 2002, Evaluation & the health professions.
[4] P. Calverley,et al. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease , 2003, Thorax.
[5] N. Hanania,et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. , 2003, Chest.
[6] A. Morice,et al. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) , 1997, The European respiratory journal.
[7] W. Hop,et al. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. , 2000, The European respiratory journal.
[8] T. Seemungal,et al. COPD exacerbations: defining their cause and prevention , 2007, The Lancet.
[9] D. Mannino,et al. International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study , 2007, The Lancet.
[10] J. Bourbeau,et al. Tiotropium in Combination with Placebo, Salmeterol, or FluticasoneSalmeterol for Treatment of Chronic Obstructive Pulmonary Disease , 2007, Annals of Internal Medicine.
[11] R. Stockley,et al. Addition of salmeterol to existing treatment in patients with COPD: a 12 month study , 2006, Thorax.
[12] S. Pocock. Safety of drug-eluting stents: demystifying network meta-analysis , 2007, The Lancet.
[13] P. Calverley,et al. Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease , 2003, European Respiratory Journal.
[14] Gordon H. Guyatt,et al. A Decision Aid for COPD patients considering inhaled steroid therapy: development and before and after pilot testing , 2007, BMC Medical Informatics Decis. Mak..
[15] S. Sahn,et al. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. , 2007, Clinical therapeutics.
[16] N. Hanania,et al. The Efficacy and Safety of Fluticasone Propionate (250 μg)/Salmeterol (50 μg) Combined in the Diskus Inhaler for the Treatment of COPD , 2003 .
[17] D. Dusser,et al. The effect of tiotropium on exacerbations and airflow in patients with COPD. , 2006, The European respiratory journal.
[18] K. Rabe,et al. Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease. , 2005, Respiratory medicine.
[19] Harold I Feldman,et al. Individual patient‐ versus group‐level data meta‐regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head , 2002, Statistics in medicine.
[20] P. Burge,et al. A double‐blind placebo‐controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[21] Douglas G. Altman,et al. Effect Measures for Meta‒Analysis of Trials with Binary Outcomes , 2008 .
[22] E. Bateman,et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. , 2002, Chest.
[23] P. Bruggmann,et al. Adherence to the Swiss guidelines for management of COPD: experience of a Swiss teaching hospital. , 2005, Swiss medical weekly.
[24] T. Lasserson,et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. , 2007, The Cochrane database of systematic reviews.
[25] J. Bourbeau,et al. Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. , 1998, Thorax.
[26] R. Sansores,et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease , 2003, European Respiratory Journal.
[27] T. Wilt,et al. Management of Stable Chronic Obstructive Pulmonary Disease: A Systematic Review for a Clinical Practice Guideline , 2007, Annals of Internal Medicine.
[28] M. Littner,et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.
[29] N. Anthonisen,et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. , 1987, Annals of internal medicine.
[30] Deborah M Caldwell,et al. Simultaneous comparison of multiple treatments: combining direct and indirect evidence , 2005, BMJ : British Medical Journal.
[31] T. Lasserson,et al. Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. , 2007, The Cochrane database of systematic reviews.
[32] T. Seemungal,et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. , 2008, American journal of respiratory and critical care medicine.
[33] T. Lasserson,et al. Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease. , 2007, The Cochrane database of systematic reviews.
[34] S. Yancey,et al. Efficacy of salmeterol xinafoate in the treatment of COPD. , 1999, Chest.
[35] S. Kesten,et al. Absence of Electrocardiographic Findings and Improved Function with Once‐Daily Tiotropium in Patients with Chronic Obstructive Pulmonary Disease , 2005, Pharmacotherapy.
[36] Douglas G. Altman,et al. Systematic Reviews in Health Care , 2001 .
[37] B. Celli,et al. Symptoms are an important outcome in chronic obstructive pulmonary disease clinical trials: results of a 3-month comparative study using the Breathlessness, Cough and Sputum Scale (BCSS). , 2003, Respiratory medicine.
[38] R. Goldstein,et al. The addition of salmeterol 50 microg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Chronic obstructive pulmonary disease. , 2002, Canadian respiratory journal.
[39] S D Walter,et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. , 1997, Journal of clinical epidemiology.
[40] M. Biraghi,et al. Efficacy of Nebulized Flunisolide Combined with Salbutamol and Ipratropium Bromide in Stable Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease , 2006, Respiration.
[41] C. D. Mathers,et al. Chronic obstructive pulmonary disease: current burden and future projections , 2006, European Respiratory Journal.
[42] C. Vogelmeier,et al. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.
[43] G. Lu,et al. Combination of direct and indirect evidence in mixed treatment comparisons , 2004, Statistics in medicine.
[44] D. Niewoehner,et al. Prevention of Exacerbations of Chronic Obstructive Pulmonary Disease with Tiotropium, a Once-Daily Inhaled Anticholinergic Bronchodilator , 2005, Annals of Internal Medicine.
[45] J. Yates,et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. , 2002, American journal of respiratory and critical care medicine.
[46] T. Lumley. Network meta‐analysis for indirect treatment comparisons , 2002, Statistics in medicine.
[47] D. D. Briggs,et al. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. , 2005, Pulmonary pharmacology & therapeutics.
[48] V. Brusasco,et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. , 2003, Thorax.
[49] R. Zuwallack,et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease , 2002, European Respiratory Journal.
[50] R. Buhl,et al. Efficacy of tiotropium bromide (Spiriva®) in patients with chronic obstructive pulmonary disease (COPD) of different severities , 2006, Pneumologie.
[51] W. Bailey,et al. Loss of bone density with inhaled triamcinolone in Lung Health Study II. , 2004, American journal of respiratory and critical care medicine.
[52] Bartolome Celli,et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.
[53] V. Brusasco,et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. , 2003, Thorax.
[54] R. Dahl,et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.
[55] D. Stryer,et al. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. , 2003, JAMA.
[56] S. Suissa. Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. , 2006, American journal of respiratory and critical care medicine.
[57] T. Bengtsson,et al. Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study , 2002, European Respiratory Journal.
[58] P. Paggiaro,et al. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease , 1998, The Lancet.
[59] G. Della Cioppa,et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. , 2002, Chest.
[60] P. Barnes. Chronic Obstructive Pulmonary Disease: A Growing but Neglected Global Epidemic , 2007, PLoS medicine.
[61] K J Rothman,et al. The continuing unethical use of placebo controls. , 1994, The New England journal of medicine.
[62] J. L. Viejo-Bañuelos,et al. Characteristics of outpatients with COPD in daily practice: The E4 Spanish project. , 2006, Respiratory medicine.
[63] R. Pauwels,et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial , 2003, The Lancet.